Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study
The Oncologist · 17.01.2025 · 30 (1)
DOI: 10.1093/oncolo/oyae206 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, online erschienen am 23.08.2024. Verfasst von Francesco Schettini und 20 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spa…. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Trieste.
Abstract (Originalsprache)
Background
The identification of the most appropriate targeted therapies for advanced cancers is challenging. We performed a molecular profiling of metastatic solid tumors utilizing a comprehensive next-generation sequencing (NGS) assay to determine genomic alterations’ type, frequency, actionability, and potential correlations with PD-L1 expression.
Methods
A total of 304 adult patients with heavily pretreated metastatic cancers treated between January 2019 and March 2021 were recruited. The CLIA-/UKAS-accredit Oncofocus assay targeting 505 genes was used on newly obtained or archived biopsies. Chi-square, Kruskal-Wallis, and Wilcoxon rank-sum tests were used where appropriate. Results were significant for P < .05.
Results
A total of 237 tumors (78%) harbored potentially actionable genomic alterations. Tumors were positive for PD-L1 in 68.9% of cases. The median number of mutant genes/tumor was 2.0 (IQR: 1.0-3.0). Only 34.5% were actionable ESCAT Tier I-II with different prevalence according to cancer type. The DNA damage repair (14%), the PI3K/AKT/mTOR (14%), and the RAS/RAF/MAPK (12%) pathways were the most frequently altered. No association was found among PD-L1, ESCAT, age, sex, and tumor mutational status. Overall, 62 patients underwent targeted treatment, with 37.1% obtaining objective responses. The same molecular-driven treatment for different cancer types could be associated with opposite clinical outcomes.
Conclusions
We highlight the clinical value of molecular profiling in metastatic solid tumors using comprehensive NGS-based panels to improve treatment algorithms in situations of uncertainty and facilitate clinical trial recruitment. However, interpreting genomic alterations in a tumor type-specific manner is critical.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain.
- Medical Oncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
- Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain.
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," 47014, Meldola, Italy.
- Oncologica UK Ltd, Cambridge CB10 1XL, United Kingdom.
- Department of Medical, Surgical and Health Sciences, University of Trieste, 34147, Trieste, Italy.
ORCID-Profile: Francesco Schettini
Förderung
- University of Trieste
Zitieren
APA
Schettini, F., Sirico, M., Loddo, M., Williams, G. H., Hardisty, K. M., Scorer, P., Thatcher, R., Rivera, P., Milani, M., Strina, C., Ferrero, G., Ungari, M., Bottin, C., Zanconati, F., de Manzini, N., Aguggini, S., Tancredi, R., Fiorio, E., Fioravanti, A., …, & Generali, D. (2025). Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study. The Oncologist, 30(1). https://doi.org/10.1093/oncolo/oyae206
Vancouver
Schettini F, Sirico M, Loddo M, Williams GH, Hardisty KM, Scorer P, et al. Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study. The Oncologist. 2025;30(1). doi:10.1093/oncolo/oyae206
BibTeX
@article{Schettini2025,
author = {Schettini, Francesco and Sirico, Marianna and Loddo, Marco and Williams, Gareth H and Hardisty, Keeda-Marie and Scorer, Paul and Thatcher, Robert and Rivera, Pablo and Milani, Manuela and Strina, Carla and Ferrero, Giuseppina and Ungari, Marco and Bottin, Cristina and Zanconati, Fabrizio and de Manzini, Nicolò and Aguggini, Sergio and Tancredi, Richard and Fiorio, Elena and Fioravanti, Antonio and Scaltriti, Maurizio and Generali, Daniele},
title = {Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {1},
doi = {10.1093/oncolo/oyae206}
}
EUVIMED